MEOX1: A Potential Drug Target and Biomarker (G4222)

Target Name: MEOX1

NCBI ID: G4222

MEOX1

MEOX1: A Potential Drug Target and Biomarker

Introduction

MEOX1 (Homeobox protein MOX-1 (isoform 1)) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the Homeobox gene family, which is known for the development and maintenance of normal cellular and tissue structures during development and throughout life. MEOX1 is a 21-kDa protein that is expressed in tissues throughout the body, and it plays a role in the regulation of cellular processes such as cell adhesion, migration, and differentiation.

Molecular Structure and Function

The Homeobox gene family consists of six proteins that are involved in the regulation of cellular processes during development and throughout life. The MEOX1 protein is one of these proteins and is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract . MEOX1 has a molecular structure that is characterized by a N-terminus, a unique disulfide bond, and a C-terminus that is involved in protein-protein interactions.

MEOX1 functions as a negative regulator of the Homeobox gene. It binds to the N-terminus of the Homeobox gene and prevents it from being translated into protein. This function is critical for the regulation of cellular processes, including cell adhesion, migration, and differentiation . MEOX1 is also involved in the regulation of tissue homeostasis and in the development of cancer.

Drug Targeting

MEOX1 is a potential drug target because of its involvement in the regulation of cellular processes that are important for human health and disease. The development of cancer is a major public health problem that has a high mortality rate and is a significant economic burden on society. The regulation of cellular processes that are involved in cancer development, such as cell adhesion, migration, and differentiation, is a promising area of 鈥嬧?媟esearch and may lead to the development of new therapeutic strategies for cancer treatment.

MEOX1 is a key regulator of the Homeobox gene family, and its function in the regulation of cellular processes is being targeted by researchers as a potential drug target. Studies have shown that MEOX1 can be inhibited by small molecules, such as inhibitors of protein-protein interactions or by drugs that can disrupt the structure of MEOX1. These inhibitors have been shown to have a beneficial effect on the regulation of cellular processes and may be a useful tool for the development of new therapeutic strategies for cancer treatment.

Biomarker

MEOX1 is also a potential biomarker for cancer. The regulation of cellular processes by MEOX1 is altered in cancer cells, and these changes can be detected by measuring the levels of MEOX1 in cancer cells. The levels of MEOX1 have been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that MEOX1 may be a useful biomarker for the diagnosis and evaluation of cancer.

Conclusion

MEOX1 is a protein that is involved in the regulation of cellular processes during development and throughout life. It is a member of the Homeobox gene family and is expressed in various tissues of the body. MEOX1 is a potential drug target and biomarker for cancer, and its function in the regulation of cellular processes is being targeted by researchers as a promising area of 鈥嬧?媟esearch. Further studies are needed to fully understand the role of MEOX1 in the regulation of cellular processes and its potential as a drug target and biomarker for cancer.

Protein Name: Mesenchyme Homeobox 1

Functions: Mesodermal transcription factor that plays a key role in somitogenesis and is specifically required for sclerotome development. Required for maintenance of the sclerotome polarity and formation of the cranio-cervical joints (PubMed:23290072, PubMed:24073994). Binds specifically to the promoter of target genes and regulates their expression. Activates expression of NKX3-2 in the sclerotome. Activates expression of CDKN1A and CDKN2A in endothelial cells, acting as a regulator of vascular cell proliferation. While it activates CDKN1A in a DNA-dependent manner, it activates CDKN2A in a DNA-independent manner. Required for hematopoietic stem cell (HSCs) induction via its role in somitogenesis: specification of HSCs occurs via the deployment of a specific endothelial precursor population, which arises within a sub-compartment of the somite named endotome

The "MEOX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEOX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets